Moderna Didn't Get Lucky With COVID. It Got a Decade of Runway. Now the Clock Is Running Out.

In 2022, Moderna sold $18.4 billion of product — almost all of it a single COVID vaccine the world bought in a panic.² Two years later, that number was $3.1 billion in Spikevax sales inside a $3.236 billion company, a 53% drop in one year and roughly an 83% collapse from the peak.¹⁴ The boom didn't taper. It fell off a cliff. And the most interesting thing about Moderna right now is not how far it fell — it's what the company quietly did with the money on the way down.

The official story is that Moderna is a COVID vaccine company whose moment has passed. That story is wrong twice over. It was never a COVID company — it was founded in 2010 to make mRNA therapeutics, originally for cancer and rare disease, with no marketed product at all until 2021.⁸ And its moment hasn't passed; it hasn't arrived. The pandemic was a cash event, not the thesis. The thesis is still in the clinic.

Here is the read worth defending: Moderna is a platform company that used a once-in-a-century windfall to buy itself a decade of R&D runway — and the bill for that bet is coming due now, not later. The next 24 months are not a managed transition from one product to the next. They are a binary inflection, where a handful of trial read-outs decide whether the platform was real or whether COVID was simply the only thing it ever made.

The windfall was the easy part. Spending it well is the test.

Look at what Moderna kept doing while its top line cratered. In 2023, with product sales already down to $6.7 billion from $18.4 billion, it spent $4.845 billion on R&D.² In 2024, with revenue halved again, it still spent $4.543 billion — more than its entire total revenue for the year.¹ That is not a company harvesting a dying product. That is a company burning a war chest to fund 45 programs, nine of them late-stage, as fast as it can.³ The pandemic cash didn't make Moderna rich. It made Moderna a venture-scale bet with a real balance sheet — $9.5 billion of cash at the end of 2024, down from $13.3 billion a year earlier.⁴ The runway is long. It is also visibly shortening.

This is why the platform framing matters and the vaccine framing misleads. A vaccine company down 83% is in terminal decline. A platform company spending more than it earns on a pipeline is either two years from validation or two years from a credibility crisis — and which one depends entirely on data that does not yet exist.

Why the whole thesis now rests on a melanoma trial that hasn't reported

The brightest light in Moderna's pipeline is mRNA-4157, an individualized cancer vaccine that prints a custom mRNA shot tuned to a patient's own tumor mutations, given alongside Merck's Keytruda. The Phase 2b KEYNOTE-942 data are genuinely striking: at three years, the combination cut the risk of recurrence or death by 49% versus Keytruda alone in resected high-risk melanoma,⁹ and the FDA handed it a Breakthrough Therapy Designation on February 22, 2023.¹⁰ If that holds, it is not a better flu shot. It is a new category of medicine, and the clearest proof the platform can do something COVID never tested it on.

But notice the tense. That 49% is a Phase 2b number, and Phase 2b numbers are where oncology dreams go to be confirmed or quietly buried. The confirmatory Phase 3, INTerpath-001 — enrolling approximately 1,089 patients with a primary endpoint of recurrence-free survival — is fully enrolled but has not reported its primary data. The figure everyone repeats as proof is, strictly, a promise that has not yet been kept. Moderna's entire 'we are a platform, not a vaccine company' argument leans on a read-out that is still pending. The platform's credibility is, right now, an enrolled trial and a press release away from being either vindicated or shattered.

The bridge product was supposed to carry the gap. It carried $25 million.

If oncology is years out, what holds the floor in the meantime? The plan was respiratory: leverage the mRNA platform's speed to launch an RSV vaccine and then combination flu/COVID shots, keeping the lights on until cancer arrives. Year one of that plan is in. mRESVIA, the RSV vaccine, sold $25 million in all of 2024 — and Moderna itself conceded the RSV sales 'did not have a significant impact on overall product sales.'⁴ Against $3.1 billion of fading Spikevax revenue, $25 million is a rounding error. The bridge product, so far, is not a bridge. It is a plank.

Watch what happened to the guidance, because the timeline tells the truth the press releases soften. In January 2024 Moderna projected roughly $4 billion in product sales and breakeven in 2026.³ Actual 2024 total revenue came in at $3.236 billion — about a quarter short of the product-sales target — and by the November 2025 Analyst Day the breakeven language had quietly become 'up to 10% revenue growth in 2026,' with the real growth load pushed out to 2027-2028 oncology and rare-disease bets.⁷ The combination flu/COVID shot, mRNA-1083, sits under EMA review and is still awaiting FDA guidance on refiling.⁷ The bridge isn't broken, but it is being rebuilt mid-crossing, and the far bank keeps moving farther away.

The honest counter: maybe a long runway is exactly the point

The fair objection is that this reads as alarmism. Moderna sits on $9.5 billion of cash, a validated manufacturing platform that demonstrably went from sequence to shipped vaccine at unprecedented speed, and a deep pipeline backed by a partner the size of Merck.⁴⁶ A company with that much runway doesn't need any single read-out to land on a calendar; it can absorb a melanoma miss and still be standing for the norovirus Phase 3 interim in 2026, the combo shots, the rare-disease programs.⁷ Optionality, the argument goes, is the whole platform thesis — you don't bet the company on one trial when you have forty-five.

That defense is real, and it is also where it gets tested. Optionality is not free — it is being purchased at more than $4.5 billion of R&D a year against a shrinking revenue base, and the market does not value a platform on the breadth of its pipeline. It values it on the first credible proof the platform makes something beyond a pandemic vaccine. mRNA-4157 is that proof point. Strip away the 45 programs and the cash cushion, and the binary remains: until a confirmatory Phase 3 turns a Phase 2b signal into an approved oncology drug, Moderna is a platform whose only commercialized output is the very vaccine category everyone says is dying. The runway is long precisely because the destination is still unproven — and runway, unlike revenue, is something you spend until it's gone.

Moderna spent a pandemic's worth of money buying time, and time is exactly what it has left to spend. The platform was never about COVID; COVID was the cash that let the platform try to prove itself on harder ground. Now the cash is thinning, the bridge product brought in $25 million, and the entire argument for what Moderna is rests on a melanoma trial that is fully enrolled and stubbornly silent. The next 24 months don't reward patience or punish impatience. They simply answer the one question the windfall let the company avoid asking: was it ever a platform, or just a single, spectacular, temporary shot?